S&P 500   3,322.98 (-0.14%)
DOW   27,178.46 (-0.08%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,322.98 (-0.14%)
DOW   27,178.46 (-0.08%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,322.98 (-0.14%)
DOW   27,178.46 (-0.08%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,322.98 (-0.14%)
DOW   27,178.46 (-0.08%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
Log in

OTCMKTS:CNBXCannabics Pharmaceuticals Stock Price, Forecast & News

$0.20
+0.00 (+1.76 %)
(As of 08/6/2020 09:30 AM ET)
Add
Compare
Today's Range
$0.19
Now: $0.20
$0.21
50-Day Range
$0.20
MA: $0.23
$0.28
52-Week Range
$0.07
Now: $0.20
$0.61
Volume55,365 shs
Average Volume399,215 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cannabics Pharmaceuticals Inc., an early stage biotechnology company, engages in the development and licensing of cannabinoid-based treatments and therapies. The company focuses on developing and marketing therapies and biotechnological tools for the relief from various ailments that respond to active ingredients sourced from the cannabis plant. It offers Cannabics SR, a medical cannabis capsules to treat cancer related cachexia/anorexia syndrome in advanced cancer patients. The company also focuses on the commercialization of a diagnostic test based on liquid biopsies of patients suffering from epithelial cancers; and development of diagnostics that monitor cancer progression and cannabinoid cancer sensitivity tests for the treatment of cancer with cannabinoid medicine. Cannabics Pharmaceuticals Inc. has a collaboration with SIMFO GmbH for circulating tumor cell drug sensitivity tests. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
Current SymbolOTCMKTS:CNBX
CUSIPN/A
Phone+1-877-4242429

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees8
Next Earnings DateN/A
OptionableNot Optionable
$0.20
+0.00 (+1.76 %)
(As of 08/6/2020 09:30 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNBX News and Ratings via Email

Sign-up to receive the latest news and ratings for CNBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cannabics Pharmaceuticals (OTCMKTS:CNBX) Frequently Asked Questions

How has Cannabics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Cannabics Pharmaceuticals' stock was trading at $0.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CNBX shares have decreased by 32.7% and is now trading at $0.2020.
View which stocks have been most impacted by Coronavirus
.

Has Cannabics Pharmaceuticals been receiving favorable news coverage?

Media coverage about CNBX stock has trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cannabics Pharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Cannabics Pharmaceuticals
.

Who are some of Cannabics Pharmaceuticals' key competitors?

What other stocks do shareholders of Cannabics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cannabics Pharmaceuticals investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), OrganiGram (OGI), KushCo (KSHB), mCig (MCIG), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), InMed Pharmaceuticals (IMLFF) and Pennsylvania R.E.I.T. (PEI).

Who are Cannabics Pharmaceuticals' key executives?

Cannabics Pharmaceuticals' management team includes the following people:
  • Mr. Eyal Barad, Co-Founder, CEO & Director (Age 54)
  • Dr. Eyal Ballan Ph.D., Co-founder, CTO & Director (Age 43)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, CFO & Principal Accounting Officer (Age 49)
  • Mr. David E. Price, Sec. & Corp. Counsel (Age 54)
  • Mr. Yasha Borstein, Chief Data Officer (Age 56)

What is Cannabics Pharmaceuticals' stock symbol?

Cannabics Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CNBX."

How do I buy shares of Cannabics Pharmaceuticals?

Shares of CNBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cannabics Pharmaceuticals' stock price today?

One share of CNBX stock can currently be purchased for approximately $0.20.

What is Cannabics Pharmaceuticals' official website?

The official website for Cannabics Pharmaceuticals is www.cannabics.com.

How can I contact Cannabics Pharmaceuticals?

Cannabics Pharmaceuticals' mailing address is #3 Bethesda Metro Center, Suite 700, BETHESDA, MD 20814, United States. The company can be reached via phone at +1-877-4242429.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.